- The share
- Press releases
- Financial calendar
- Financial reports
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- CODE OF CONDUCT
- Thank you
The study from Lund published in Nature Communications
Today the first scientific article was published which describes the results after storage during the transport of donated hearts using the method developed by Professor Stig Steen in Lund, and to which XVIVO has the commercial rights. The article was published in Nature Communications today and the article's first author is Professor Johan Nilsson. See below link for the article in full:
The study describes the results for six transplant patients, that received a donated heart after it was stored during transport using the new technology. These six patients are compared with 25 patients where the donated heart is stored during transport with traditional cold preservation. After six months, all patients (100%) transplanted with the new technology are alive and without serious complications related to heart function or rejection. The corresponding outcome in the control group of 25 patients was 72%. The results show that the method is safe and functional for clinical application.
June 12, 2020
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101, firstname.lastname@example.org
Dag Andersson, CEO, +46 76 643 3031, email@example.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
The information was submitted for publication, through the agency of the contact person set out above, at 4.30 pm CET on June 12, 2020.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.